scholarly journals Quality of life trajectories during the first three years after diagnosis of breast cancer: the NEON-BC study

2019 ◽  
Author(s):  
Luisa Lopes-Conceição ◽  
Mariana Brandão ◽  
Natália Araújo ◽  
Milton Severo ◽  
Teresa Dias ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Sleep Quality ◽  
Patient Reported Outcomes ◽  
Life Questionnaire ◽  
European Organization ◽  
Life Trajectories ◽  
Patient Reported ◽  
Anxiety Depression

Abstract Background We aimed to identify and characterize quality of life trajectories up to 3 years after breast cancer diagnosis. Methods A total of 460 patients were evaluated at baseline (before treatments), and after 1- and 3-years. Patient-reported outcomes, including quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, QLQ-C30), anxiety, depression and sleep quality, were assessed in all evaluations. Model-based clustering was used to identify quality of life trajectories. Results We identified four trajectories without intersection during 3 years. The two trajectories characterized by better quality of life depicted relatively stable scores; in the other trajectories, quality of life worsened until 1 year, though in one of them the score at 3 years improved. Sociodemographic and clinical characteristics at baseline did not differ between trajectories, except for mastectomy, which was higher in the worst trajectory. Anxiety, depression and poor sleep quality increased from the best to the worst trajectory. Conclusions The type of surgery and the variation of other patient-reported outcomes were associated with the course of quality of life over 3 years. More research to understand the heterogeneity of individual trajectories within these major patterns of variation is needed.

The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials

2008 ◽  
Vol 26 (8) ◽  
pp. 1355-1363 ◽  
Author(s):  
Carolyn C. Gotay ◽  
Crissy T. Kawamoto ◽  
Andrew Bottomley ◽  
Fabio Efficace
Keyword(s):  
Quality Of Life ◽  
Clinical Trials ◽  
Patient Reported Outcomes ◽  
Prognostic Significance ◽  
Cancer Clinical Trials ◽  
Life Questionnaire ◽  
European Organization ◽  
Patient Reported ◽  
The Impact

Purpose Patient-reported outcomes (PROs), routinely collected as a part of cancer clinical trials, have been linked with survival in numerous clinical studies, but a comprehensive critical review has not been reported. This study systematically assessed the impact of PROs on patient survival after a cancer diagnosis within the context of clinical trials. Design Cancer clinical trials that assessed baseline PROs and mortality were identified through MEDLINE (through December 2006) supplemented by the Cochrane database, American Society of Clinical Oncology/European Society for Medical Oncology abstracts and hand searches. Inclusion criteria were publication in English language and use of multivariate analyses of PROs that controlled for one or more clinical factors. Two raters reviewed each study, abstracted data, and assessed study quality; two additional raters verified abstractions. Results In 36 of 39 studies (N = 13,874), at least one PRO was significantly associated with survival (P < .05) in multivariate analysis, with varying effect sizes. Studies of lung (n = 12) and breast cancer (n = 8) were most prevalent. The most commonly assessed PRO was quality of life, measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 in 56% of studies. Clinical variables adjusted for included performance status (PS), treatment arm, stage, weight loss, and serum markers. Results indicated that PROs provide distinct prognostic information beyond standard clinical measures in cancer clinical trials. Conclusion PROs might be considered for stratification purposes in future trials, as they were often better predictors of survival than PS. Studies are needed to determine whether interventions that improve PROs also increase survival and to identify explanatory mechanisms through which PROs relate to survival.

scholarly journals Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points

2021 ◽  
Author(s):  
Ernest Law ◽  
Roya Gavanji ◽  
Sarah Walsh ◽  
Anja Haltner ◽  
Rebecca McTavish ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Advanced Breast Cancer ◽  
Patient Reported Outcomes ◽  
Indirect Comparison ◽  
Advanced Breast ◽  
Life Questionnaire ◽  
Patient Reported ◽  
Global Quality Of Life

Aim: To assess the relative impact of palbociclib plus fulvestrant (PAL + FUL) and abemaciclib plus fulvestrant (ABEM + FUL) on patient-reported outcomes in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Patients & methods: Anchored matching-adjusted indirect comparisons were conducted using individual patient data from PALOMA-3 (PAL + FUL) and summary-level data from MONARCH-2 (ABEM + FUL). Outcomes included the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30) and its breast cancer-specific module (QLQ-BR23). Results: Significantly different changes from baseline favoring PAL + FUL compared with ABEM + FUL were observed in global quality of life (6.95 [95% CI: 2.19–11.71]; p = 0.004) and several functional/symptom scales, including emotional functioning, nausea/vomiting, appetite loss, diarrhea and systemic therapy side effects. Conclusion: PAL + FUL was associated with more favorable patient-reported outcomes than ABEM + FUL in patients with HR+/HER2- advanced breast cancer.

scholarly journals Factors associated with depression and the relationship to quality of life among Saudi women with breast cancer

2020 ◽  
Vol 11 (4) ◽  
pp. 43
Author(s):  
Monefah Al-Shammari ◽  
Amani Khalil
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Life Questionnaire ◽  
Primary Therapy ◽  
Convenience Sample ◽  
Saudi Women ◽  
Patient Reported ◽  
Eortc Qlq ◽  
The Relationship

Background and objective: Breast cancer is the most common malignancy among women worldwide, diagnosis and treatment and the months following primary therapy associated with different psychological symptoms that affect quality of life (QoL) in most women with breast cancer. The aim of this study was to identify the relationship between depression and quality of life QoL among Saudi women with breast cancer.Methods: Design: This is a descriptive, cross-sectional study. Methods: A convenience sample of 370 women with breast cancer was recruited from the out-clinic in King Faisal Specialist Hospital \& Research Center (KFSH&RC). Data were collected using self-report tools derived from the Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Distress-Depression-Short Form; the EORTC quality of life questionnaire (QLQ) (EORTC QLQ-C30, v.3.0 and EORTC QLQ-BR23); and from the Demographic and Clinical Data Sheet.Results: The correlation between depression and global health status with functioning subscales for the women was negative (Pearson’s r = -.357, p < .001; r = -.368, p < .001); whereas a positive correlation was found between depression and symptom subscales, together with its items.Conclusions: This study shows that depression is associated with QoL among Saudi women diagnosed with breast cancer. Therefore, depression affects upon QoL among the breast cancer population. However, enhancement of mental health statuses and psychological interventions helps to reduce the severity of depression and improves health related QoL among this population.

scholarly journals Qualidade de Vida Relacionada à Saúde de Pacientes com Câncer de Mama: Revisão Integrativa da Literatura

2020 ◽  
Vol 66 (1) ◽  
Author(s):  
Monique Binotto ◽  
Gilberto Schwartsmann
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cáncer De Mama ◽  
Life Questionnaire ◽  
European Organization ◽  
Quality Of Life Questionnaire ◽  
Cancer Breast ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

Introdução: O câncer de mama pode alterar a qualidade de vida relacionada à saúde das pacientes. Objetivo: Compreender o impacto da quimioterapia para câncer de mama na qualidade de vida relacionada à saúde de pacientes. Método: Trata-se de uma revisão integrativa da literatura, compreendendo artigos publicados entre 2007 e 2019, disponíveis nas bases de dados PubMed, LILACS e SciELO. Analisaram-se 25 artigos na íntegra. Resultados: Os questionários mais frequentemente utilizados nos estudos foram o European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) e o módulo complementar European Organization for Research and Treatment of Cancer Breast Cancer-specific Quality of Life Questionnaire (EORTC QLQ-BR23). Em relação às alterações da qualidade de vida, a saúde global diminui durante a quimioterapia, mas pode melhorar após o término do tratamento. O aumento dos sintomas é relatado em diversos estudos e prejudicou a qualidade de vida relacionada à saúde das pacientes. Entretanto, os sintomas diminuem após o término da quimioterapia, exceto para algumas escalas. As escalas de imagem corporal, função sexual e funcionamento físico pioram ao longo do tratamento. A qualidade de vida mental/psicológica tem oscilações durante o tratamento, assim como a escala sobre as relações sociais. Conclusão: A qualidade de vida relacionada à saúde de mulheres com câncer de mama é afetada negativamente pelo tratamento quimioterápico, expressando maior impacto nas escalas de sintomas.

QUALIDADE DE VIDA RELACIONADA À SAÚDE DE MULHERES IDOSAS EM TRATAMENTO DE CÂNCER DE MAMA

2022 ◽  
Author(s):  
LIA RAQUEL DE CARVALHO VIANA ◽  
GERLANIA RODRIGUES SALVIANO FERREIRA ◽  
STHEPHANIE DE ABREU FREITAS ◽  
KATIA NEYLA DE FREITAS MACEDO COSTA
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Social Science ◽  
Cáncer De Mama ◽  
Life Questionnaire ◽  
European Organization ◽  
Quality Of Life Questionnaire ◽  
The Social

OBJETIVO: AVALIAR A QUALIDADE DE VIDA RELACIONADA À SAÚDE DE MULHERES IDOSAS EM TRATAMENTO DE CÂNCER DE MAMA. MÉTODO: ESTUDO TRANSVERSAL, DESCRITIVO, COM ABORDAGEM QUANTITATIVA, REALIZADO COM 57 MULHERES IDOSAS EM TRATAMENTO DE CÂNCER DE MAMA. A COLETA DE DADOS OCORREU DURANTE OS MESES DE JUNHO A NOVEMBRO DE 2019, POR MEIO DE UM INSTRUMENTO SEMIESTRUTURADO PARA OBTENÇÃO DE DADOS SOCIODEMOGRÁFICOS E CLÍNICOS E OS QUESTIONÁRIOS EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE “CORE” 30 E QUALITY OF LIFE QUESTIONNAIRE – BREAST CANCER 23. OS DADOS FORAM ANALISADOS DE FORMA DESCRITIVA COM O AUXÍLIO DO STATISTICAL PACKAGE FOR THE SOCIAL SCIENCE FOR WINDOWS, VERSÃO 22.0. O PROJETO FOI APROVADO PELO COMITÊ DE ÉTICA EM PESQUISA SOB PARECER Nº 3.293.768. RESULTADOS: NA QUALIDADE DE VIDA GERAL, OBSERVOU-SE QUE AS IDOSAS APRESENTARAM BOA MÉDIA NA ESCALA DE SAÚDE GLOBAL E RAZOÁVEL NA ESCALA FUNCIONAL, DESTACANDO-SE A FUNÇÃO SOCIAL. JÁ A ESCALA DE SINTOMAS APRESENTOU MÉDIA BAIXA, DESTACANDO-SE A DIFICULDADE FINANCEIRA, INSÔNIA, FADIGA E DOR. NO QUESTIONÁRIO ESPECÍFICO, A ESCALA FUNCIONAL APRESENTOU MAIOR MÉDIA, COM DESTAQUE POSITIVO PARA A IMAGEM CORPORAL. NA ESCALA DE SINTOMAS, OS EFEITOS COLATERAIS E OS SINTOMAS DA MAMA FORAM OS QUE MAIS CONTRIBUÍRAM PARA A DETERIORAÇÃO DA QUALIDADE DE VIDA. CONCLUSÃO: A QUALIDADE DE VIDA GLOBAL APRESENTOU-SE BOA, NO ENTANTO, A MESMA SOFRE IMPACTOS DEVIDO AOS EFEITOS COLATERAIS AO TRATAMENTO.

scholarly journals Quality of life and mental health in breast cancer survivors compared with non-cancer controls: a study of patient-reported outcomes in the United Kingdom

2020 ◽  
Author(s):  
Helena Carreira ◽  
Rachael Williams ◽  
Harley Dempsey ◽  
Susannah Stanway ◽  
Liam Smeeth ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Primary Care ◽  
Cancer Survivors ◽  
Patient Reported Outcomes ◽  
Breast Cancer Survivors ◽  
Patient Reported ◽  
History Of ◽  
History Of Cancer

Abstract Purpose There is limited high-quality evidence on quality of life, anxiety, and depressive symptoms in breast cancer survivors and women with no history of cancer. We aimed to address this by comparing patient-reported outcomes between breast cancer survivors and women with no history of breast cancer. Methods Breast cancer survivors and women with no prior cancer were selected from the UK Clinical Practice Research Datalink GOLD primary care database, which includes population-based primary care electronic health record data. Breast cancer survivors and controls were frequency matched by age and primary care practice. Outcomes were assessed with validated instruments via postal questionnaire. Linear and logistic regression models were fitted to estimate adjusted associations between breast cancer survivorship and outcomes. Results A total of 356 breast cancer survivors (8.1 years post diagnosis) and 252 women with no prior cancer participated in the study. Compared with non-cancer controls, breast cancer survivors had poorer QoL in the domains of cognitive problems (adjusted β (aβ) = 1.4, p = 0.01), sexual function (aβ = 1.7, p = 0.02) and fatigue (aβ = 1.3, p = 0.01), but no difference in negative feelings, positive feelings, pain, or social avoidance. Breast cancer survivors had higher odds of borderline-probable anxiety (score ≥ 8) (adjusted OR = 1.47, 95%CI:1.15–1.87), but no differences in depression. Advanced stage at diagnosis and chemotherapy treatment were associated with poorer QoL. Conclusions Compared with women with no history of cancer, breast cancer survivors report more problems with cognition, sexual function, fatigue, and anxiety, particularly where their cancer was advanced and/or treated with chemotherapy. Implications for Cancer Survivors Breast cancer survivors with more advanced disease and/or treated with chemotherapy should be closely monitored and, when possible, offered evidence-based intervention for fatigue, cognitive dysfunction, and sexual problems.

Sign in / Sign up

Export Citation Format

Share Document